Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma
A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with 13 patients (68%) successfully completing treatmen...
Gespeichert in:
| Veröffentlicht in: | Journal of immunotherapy (1997) 2012-10, Vol.35 (8), p.615-620 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 620 |
|---|---|
| container_issue | 8 |
| container_start_page | 615 |
| container_title | Journal of immunotherapy (1997) |
| container_volume | 35 |
| creator | PILON-THOMAS, Shari KUHN, Lisa WEBER, Jeffrey MULE, James J SARNAIK, Amod A ELLWANGER, Sabine JANSSEN, William ROYSTER, Erica MARZBAN, Suroosh KUDCHADKAR, Ragini ZAGER, Jonathan GIBNEY, Geoffrey SONDAK, Vernon K |
| description | A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with 13 patients (68%) successfully completing treatment. An overall response rate (partial and complete responses) of 26% by intention to treat was achieved with a median follow-up time of 10 months. Of the 13 treated patients, there were 2 complete responses and 3 partial responses (38% response rate among treated patients), along with 4 patients with stable disease ranging from 2+ to 24+months. Three of the 4 patients with stable disease have had disease control without additional therapy, including one at 24+ months. Adoptive therapy with infiltrating lymphocytes is labor intensive but feasible and has a high response rate in treated patients. |
| doi_str_mv | 10.1097/cji.0b013e31826e8f5f |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1291608700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1291608700</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-47b7c72e775adbc5fe7ef639c3116103decfb2a6335ab0e92feb3582820d84243</originalsourceid><addsrcrecordid>eNpdkE9r3DAQxUVoaJJNv0EIuhR6caL_so_LkrZbtuSyORtZHqVabMuR5JD99vGy2wZ6msfM780wD6EbSu4oqfS93fk70hDKgdOSKSiddGfokkquCyEp_3TQTBSVlPoCXaW0I4QpJthndMFYVSmu9CV6e3DOW2P3ODi8bMOY_SvgFXQd3kYzJAfxMNlOfYiFH5zvcjTZD894s-_HP8HuMyS8dHnmjp0RBm_wemgnm30YsAsR_4ZsUp59dpadGUJvrtG5M12CL6e6QE_fH7arn8Xm8cd6tdwUVpQsF0I32moGWkvTNlY60OAUryynVFHCW7CuYUZxLk1DoGIOGi5LVjLSloIJvkDfjnvHGF4mSLnufbLzf2aAMKWasooqUmpCZlQcURtDShFcPUbfm7ivKakPmderX-v6_8xn2-3pwtT00P4z_Q15Br6eAJOs6dycq_Xpg1NCEl1q_g4x-42c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1291608700</pqid></control><display><type>article</type><title>Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>PILON-THOMAS, Shari ; KUHN, Lisa ; WEBER, Jeffrey ; MULE, James J ; SARNAIK, Amod A ; ELLWANGER, Sabine ; JANSSEN, William ; ROYSTER, Erica ; MARZBAN, Suroosh ; KUDCHADKAR, Ragini ; ZAGER, Jonathan ; GIBNEY, Geoffrey ; SONDAK, Vernon K</creator><creatorcontrib>PILON-THOMAS, Shari ; KUHN, Lisa ; WEBER, Jeffrey ; MULE, James J ; SARNAIK, Amod A ; ELLWANGER, Sabine ; JANSSEN, William ; ROYSTER, Erica ; MARZBAN, Suroosh ; KUDCHADKAR, Ragini ; ZAGER, Jonathan ; GIBNEY, Geoffrey ; SONDAK, Vernon K</creatorcontrib><description>A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with 13 patients (68%) successfully completing treatment. An overall response rate (partial and complete responses) of 26% by intention to treat was achieved with a median follow-up time of 10 months. Of the 13 treated patients, there were 2 complete responses and 3 partial responses (38% response rate among treated patients), along with 4 patients with stable disease ranging from 2+ to 24+months. Three of the 4 patients with stable disease have had disease control without additional therapy, including one at 24+ months. Adoptive therapy with infiltrating lymphocytes is labor intensive but feasible and has a high response rate in treated patients.</description><identifier>ISSN: 1524-9557</identifier><identifier>EISSN: 1537-4513</identifier><identifier>DOI: 10.1097/cji.0b013e31826e8f5f</identifier><identifier>PMID: 22996367</identifier><identifier>CODEN: JOIMF8</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Cyclophosphamide - administration & dosage ; Dermatology ; Female ; Follow-Up Studies ; Hematologic and hematopoietic diseases ; Humans ; Immunotherapy ; Immunotherapy, Adoptive - methods ; Interleukin-2 - administration & dosage ; Lymphocytes, Tumor-Infiltrating - immunology ; Lymphocytes, Tumor-Infiltrating - transplantation ; Lymphopenia - chemically induced ; Male ; Medical sciences ; Melanoma - immunology ; Melanoma - secondary ; Melanoma - therapy ; Middle Aged ; Other diseases. Hematologic involvement in other diseases ; Pharmacology. Drug treatments ; Pilot Projects ; Skin Neoplasms - immunology ; Skin Neoplasms - pathology ; Skin Neoplasms - therapy ; Treatment Outcome ; Tumor Cells, Cultured ; Tumors of the skin and soft tissue. Premalignant lesions ; Vidarabine - administration & dosage ; Vidarabine - analogs & derivatives</subject><ispartof>Journal of immunotherapy (1997), 2012-10, Vol.35 (8), p.615-620</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-47b7c72e775adbc5fe7ef639c3116103decfb2a6335ab0e92feb3582820d84243</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26450787$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22996367$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PILON-THOMAS, Shari</creatorcontrib><creatorcontrib>KUHN, Lisa</creatorcontrib><creatorcontrib>WEBER, Jeffrey</creatorcontrib><creatorcontrib>MULE, James J</creatorcontrib><creatorcontrib>SARNAIK, Amod A</creatorcontrib><creatorcontrib>ELLWANGER, Sabine</creatorcontrib><creatorcontrib>JANSSEN, William</creatorcontrib><creatorcontrib>ROYSTER, Erica</creatorcontrib><creatorcontrib>MARZBAN, Suroosh</creatorcontrib><creatorcontrib>KUDCHADKAR, Ragini</creatorcontrib><creatorcontrib>ZAGER, Jonathan</creatorcontrib><creatorcontrib>GIBNEY, Geoffrey</creatorcontrib><creatorcontrib>SONDAK, Vernon K</creatorcontrib><title>Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma</title><title>Journal of immunotherapy (1997)</title><addtitle>J Immunother</addtitle><description>A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with 13 patients (68%) successfully completing treatment. An overall response rate (partial and complete responses) of 26% by intention to treat was achieved with a median follow-up time of 10 months. Of the 13 treated patients, there were 2 complete responses and 3 partial responses (38% response rate among treated patients), along with 4 patients with stable disease ranging from 2+ to 24+months. Three of the 4 patients with stable disease have had disease control without additional therapy, including one at 24+ months. Adoptive therapy with infiltrating lymphocytes is labor intensive but feasible and has a high response rate in treated patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Dermatology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Interleukin-2 - administration & dosage</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Lymphocytes, Tumor-Infiltrating - transplantation</subject><subject>Lymphopenia - chemically induced</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma - immunology</subject><subject>Melanoma - secondary</subject><subject>Melanoma - therapy</subject><subject>Middle Aged</subject><subject>Other diseases. Hematologic involvement in other diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Skin Neoplasms - immunology</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - therapy</subject><subject>Treatment Outcome</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><subject>Vidarabine - administration & dosage</subject><subject>Vidarabine - analogs & derivatives</subject><issn>1524-9557</issn><issn>1537-4513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE9r3DAQxUVoaJJNv0EIuhR6caL_so_LkrZbtuSyORtZHqVabMuR5JD99vGy2wZ6msfM780wD6EbSu4oqfS93fk70hDKgdOSKSiddGfokkquCyEp_3TQTBSVlPoCXaW0I4QpJthndMFYVSmu9CV6e3DOW2P3ODi8bMOY_SvgFXQd3kYzJAfxMNlOfYiFH5zvcjTZD894s-_HP8HuMyS8dHnmjp0RBm_wemgnm30YsAsR_4ZsUp59dpadGUJvrtG5M12CL6e6QE_fH7arn8Xm8cd6tdwUVpQsF0I32moGWkvTNlY60OAUryynVFHCW7CuYUZxLk1DoGIOGi5LVjLSloIJvkDfjnvHGF4mSLnufbLzf2aAMKWasooqUmpCZlQcURtDShFcPUbfm7ivKakPmderX-v6_8xn2-3pwtT00P4z_Q15Br6eAJOs6dycq_Xpg1NCEl1q_g4x-42c</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>PILON-THOMAS, Shari</creator><creator>KUHN, Lisa</creator><creator>WEBER, Jeffrey</creator><creator>MULE, James J</creator><creator>SARNAIK, Amod A</creator><creator>ELLWANGER, Sabine</creator><creator>JANSSEN, William</creator><creator>ROYSTER, Erica</creator><creator>MARZBAN, Suroosh</creator><creator>KUDCHADKAR, Ragini</creator><creator>ZAGER, Jonathan</creator><creator>GIBNEY, Geoffrey</creator><creator>SONDAK, Vernon K</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20121001</creationdate><title>Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma</title><author>PILON-THOMAS, Shari ; KUHN, Lisa ; WEBER, Jeffrey ; MULE, James J ; SARNAIK, Amod A ; ELLWANGER, Sabine ; JANSSEN, William ; ROYSTER, Erica ; MARZBAN, Suroosh ; KUDCHADKAR, Ragini ; ZAGER, Jonathan ; GIBNEY, Geoffrey ; SONDAK, Vernon K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-47b7c72e775adbc5fe7ef639c3116103decfb2a6335ab0e92feb3582820d84243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Dermatology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Interleukin-2 - administration & dosage</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Lymphocytes, Tumor-Infiltrating - transplantation</topic><topic>Lymphopenia - chemically induced</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma - immunology</topic><topic>Melanoma - secondary</topic><topic>Melanoma - therapy</topic><topic>Middle Aged</topic><topic>Other diseases. Hematologic involvement in other diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Skin Neoplasms - immunology</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - therapy</topic><topic>Treatment Outcome</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><topic>Vidarabine - administration & dosage</topic><topic>Vidarabine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PILON-THOMAS, Shari</creatorcontrib><creatorcontrib>KUHN, Lisa</creatorcontrib><creatorcontrib>WEBER, Jeffrey</creatorcontrib><creatorcontrib>MULE, James J</creatorcontrib><creatorcontrib>SARNAIK, Amod A</creatorcontrib><creatorcontrib>ELLWANGER, Sabine</creatorcontrib><creatorcontrib>JANSSEN, William</creatorcontrib><creatorcontrib>ROYSTER, Erica</creatorcontrib><creatorcontrib>MARZBAN, Suroosh</creatorcontrib><creatorcontrib>KUDCHADKAR, Ragini</creatorcontrib><creatorcontrib>ZAGER, Jonathan</creatorcontrib><creatorcontrib>GIBNEY, Geoffrey</creatorcontrib><creatorcontrib>SONDAK, Vernon K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of immunotherapy (1997)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PILON-THOMAS, Shari</au><au>KUHN, Lisa</au><au>WEBER, Jeffrey</au><au>MULE, James J</au><au>SARNAIK, Amod A</au><au>ELLWANGER, Sabine</au><au>JANSSEN, William</au><au>ROYSTER, Erica</au><au>MARZBAN, Suroosh</au><au>KUDCHADKAR, Ragini</au><au>ZAGER, Jonathan</au><au>GIBNEY, Geoffrey</au><au>SONDAK, Vernon K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma</atitle><jtitle>Journal of immunotherapy (1997)</jtitle><addtitle>J Immunother</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>35</volume><issue>8</issue><spage>615</spage><epage>620</epage><pages>615-620</pages><issn>1524-9557</issn><eissn>1537-4513</eissn><coden>JOIMF8</coden><abstract>A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with 13 patients (68%) successfully completing treatment. An overall response rate (partial and complete responses) of 26% by intention to treat was achieved with a median follow-up time of 10 months. Of the 13 treated patients, there were 2 complete responses and 3 partial responses (38% response rate among treated patients), along with 4 patients with stable disease ranging from 2+ to 24+months. Three of the 4 patients with stable disease have had disease control without additional therapy, including one at 24+ months. Adoptive therapy with infiltrating lymphocytes is labor intensive but feasible and has a high response rate in treated patients.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>22996367</pmid><doi>10.1097/cji.0b013e31826e8f5f</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1524-9557 |
| ispartof | Journal of immunotherapy (1997), 2012-10, Vol.35 (8), p.615-620 |
| issn | 1524-9557 1537-4513 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1291608700 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Cyclophosphamide - administration & dosage Dermatology Female Follow-Up Studies Hematologic and hematopoietic diseases Humans Immunotherapy Immunotherapy, Adoptive - methods Interleukin-2 - administration & dosage Lymphocytes, Tumor-Infiltrating - immunology Lymphocytes, Tumor-Infiltrating - transplantation Lymphopenia - chemically induced Male Medical sciences Melanoma - immunology Melanoma - secondary Melanoma - therapy Middle Aged Other diseases. Hematologic involvement in other diseases Pharmacology. Drug treatments Pilot Projects Skin Neoplasms - immunology Skin Neoplasms - pathology Skin Neoplasms - therapy Treatment Outcome Tumor Cells, Cultured Tumors of the skin and soft tissue. Premalignant lesions Vidarabine - administration & dosage Vidarabine - analogs & derivatives |
| title | Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A47%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Adoptive%20Cell%20Transfer%20of%20Tumor-infiltrating%20Lymphocytes%20After%20Lymphopenia%20Induction%20for%20Metastatic%20Melanoma&rft.jtitle=Journal%20of%20immunotherapy%20(1997)&rft.au=PILON-THOMAS,%20Shari&rft.date=2012-10-01&rft.volume=35&rft.issue=8&rft.spage=615&rft.epage=620&rft.pages=615-620&rft.issn=1524-9557&rft.eissn=1537-4513&rft.coden=JOIMF8&rft_id=info:doi/10.1097/cji.0b013e31826e8f5f&rft_dat=%3Cproquest_cross%3E1291608700%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1291608700&rft_id=info:pmid/22996367&rfr_iscdi=true |